International Journal of Medicine
ISSN (P): 1468-3814; ISSN (e): 2667-7008

https://theinternationalmedicine.com/



Volume: 7(12) 2025

Original Research

Recent Advancements in the Clinical Medical Field: A 2024-2025 Overview

[1]Dr Jerome Brathwaite, [2]Dr Crystal Henry,[3]Dr Sharique Ahmad,[4]Dr. Pushpendra D. Pratap, [5]Dr Abdul Naeem,[6] Dr Mehnaz Khan

[1] *Head of Department, Clinical Foundations , American University of Barbados, School of medicine. Wildey, St.Michael, Barbados.*
[2]*Dr Crystal Henry, Cell Biology lecturer, Department of Premedical Sciences, American University of Barbados, School of medicine. Wildey, St.Michael, Barbados.*
[3]*Professor, Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow, Uttar Pradesh, India- 226003*
[4]*Dr. Pushpendra D. Pratap, Research Analyst, Department of Biochemistry, Era's Lucknow Medical College & Hospital, Era University, Lucknow, Uttar Pradesh, India- 226003*
[5]*Dr Abdul Naeem, Research Analyst, Research Metabolic Unit, Era University, Lucknow, Uttar Pradesh, India- 226003*
[6]*Dr Mehnaz Khan, Junior Resident, Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow, Uttar Pradesh, India- 226003*

Received: 21 Oct 2025 / Accepted: 19 Nov 2025

Abstract

Introduction: Clinical medicine experienced significant change in 2024-2025, with noteworthy improvements in digital care, treatments, and diagnostics. With the development of genomics and molecular profiling, precision medicine is a prime example, enabling highly customized therapy of metabolic disorders, cancer, and inherited diseases. In cancer, newer immunotherapy generations, modified CAR-T cells, and bispecific antibodies are shown increased efficacy with fewer adverse effects. The use of mRNA vaccines and monoclonal antibody platforms for influenza, respiratory syncytial virus (RSV), and new pathogens has changed the treatment of infectious diseases. Concurrently, concepts like bacteriophage therapy and machine learning-based antibiotic discovery are experiencing a resurgence due to the worldwide problem of antimicrobial resistance. In the medical industry, digital health solutions are becoming more and more crucial. Artificial intelligence is now being used in imaging, pathology, and therapeutic decision-making, which benefits from the assistance for more rapid diagnosis and individualized treatment regimens. For patients with chronic diseases, wearable biosensors and telemedicine platforms are improving monitoring and continuity of care. Although regulatory approval is still highly cautious, psychedelic-assisted therapy for depression and post-traumatic stress disorder have advanced to late-stage clinical trials. At the same time, regenerative medicine has made great strides, with stem cell-derived organoids and tissue-engineered transplants on the verge of clinical use. The ethical control, safety, cost, and access issues still exist despite these developments. When considered collectively, the major developments in clinical medicine that are projected for 2024 and 2025 signify a paradigm change for the discipline. As such, they present both the opportunity for care transformation and the difficulty of responsible implementation.

Keywords: *Immunotherapy, Digital health, Psychedelics, Regenerative medicine, Clinical medicine, Precision health, Antibiotic resistance*

Introduction

The development and use of cutting-edge medical technology have undergone enormous change in recent years. Medical professionals can now employ previously unattainable techniques and treatments thanks to developments in molecular biology, computing, and translational research [1] [2]. This article discusses the consequences of these developments for future healthcare and politics while summarizing the significant advancements in several medical sectors.

The two most innovative facets of the contemporary medical paradigm are precision medicine and genetic technologies. Whole-genome and exome sequencing are being used more frequently in pharmacogenomics, rare genetic illnesses, and cancer treatment as genetic sequencing becomes more accessible [3]. The initial foundation of precision medicine has been changed to clinical-genomic programs that help doctors to locate the exact genetic mutations and give the right drugs. In addition, gene-editing methods such as CRISPR-Cas9 and base-editing are slowly becoming a reality, especially for cases of single-gene diseases like sickle cell disease and inherited retinal dystrophies [4]. Besides, pharmacogenomic testing is allowing doctors to pick the safest and most effective drugs for each patient, thus, leading to improved outcomes in a wide range of diseases like cancer, cardiovascular diseases, and neural disorders [5][6].

The integration of artificial intelligence (AI) into everyday clinical practice is a major factor in the healthcare innovation. At present, machine learning tools are used for the analysis of medical images, prediction of disease probabilities, and clinical decisions recommendations to doctors [7]. Furthermore, several recent studies provide evidence that natural language processing (NLP) can quickly and accurately extract the most relevant information from unstructured texts or data, e.g., doctors' notes or pathology reports, for the identification of adverse drug reactions and the facilitation of patient safety [8][9]. Meanwhile, AI-based solutions are involved in the updating of digital health records which, in turn, are used for patient risk assessments, triage decisions, and clinical workflows optimization [10]. Nevertheless, issues concerning data bias, model explainability, and the provision of safe and ethical use of AI in real-world healthcare scenarios are still present along with these developments [11].

One of the most revolutionary changes in medical diagnostics is the rise of liquid biopsy

Non-invasive tests coupled with liquid biopsies might be the next big thing in medical diagnostics possibly resulting in the disappearance of traditional tissue biopsies. To this end, oncologists can detect cancer-related targets in a blood sample such as circulating tumour DNA and exosomal RNA, hence cancers can be found and even monitored at the very earliest stages [12] [13]. Moreover, the employment of microfluidic and nanotechnology-based devices in detecting these markers is greatly facilitating the transition of such testing from mere experiments to a regular clinical practice [14].

Analogously, the study of the microbiome has revealed the absolute necessity of our bacterial comrades that live by us for our general well-being. The term dysbiosis refers to an imbalance in the gut microbiota which has been connected to metabolic diseases, autoimmune disorders, and even some psychological conditions [15] [16]. Scientists are moving closer to the point where they will be able to treat such imbalances by means of faecal microbiota transplantation, next-generation probiotics, and probiotic-prebiotic (synbiotic) products that not only support microbial activity but also invigorate the immune system [17].

Neuroimmunology and regenerative medicine have been very attractive fields recently leading to a plethora of recovery and treatment options. Inventions that use technologies such as stem-cell-derived organoids, lab-grown tissues, and cell therapies from research labs are gradually but definitely making the transition from the experimental field to the real clinical world [18]. Meanwhile, personalized immune therapies and monoclonal antibodies are exciting the patients with complicated neurological diseases. Excluding a few such disorders as Alzheimer's disease and multiple sclerosis, the clinical trial results have turned out to be such that these tactics are flipping the doctors' way of treating neurodegenerative and demyelinating disorders [19] [20].

Furthermore, biological inventions, digital health, and telemedicine have been merged as the core components of modern healthcare. Patients with chronic conditions are empowered to take care of themselves and stay in touch with health professionals at the same time through wearable biosensors, smartphone monitoring devices, and virtual consultation platforms [21].

Just the innovations of the first part alone, which were topics ranging from genomics, gene editing, artificial intelligence, microbiome research, and regenerative medicine, signal very clearly that clinical science is shifting towards personalized, data-driven, and patient-centered healthcare. In fact, these technological innovations are not only reshaping the face of diagnosis and treatment but, to a large extent, they are also the main drivers of the worldwide revolution of preventive healthcare. As AI-powered diagnostics, CRISPR-based gene therapies, and digital health solutions evolve and get more accessible, they indeed offer the possibility of improved patients' outcomes and quality of life. Still, researchers and clinicians working closely together will be required for a long time to solve safety and ethical issues before their full potential can be unlocked.

This review highlights that it is a wise and deliberate decision to carefully integrate these new technological breakthroughs into medical practice and facilitate the transition to a more exact, empathetic, and less discriminatory healthcare future.

1. Precision Medicine and Genomic Applications

Instead of treating everyone the same way, precision medicine uses each patient's unique genetic and molecular profile to customize therapeutic approaches. Nowadays, whole genome sequencing (WGS) and whole exome sequencing (WES) are more widely available and being incorporated into standard clinical procedures, especially in pharmacogenomics, uncommon genetic disorders, and oncology [22] [23]. Sickle cell anaemia and retinal dystrophies are examples of monogenic illnesses for which gene therapy is being advanced by CRISPR-Cas9 and base-editing technologies [24]. Additionally, pharmacogenomics screening is being utilized more and more to forecast drug toxicity and efficacy, which helps choose the best treatment plans for diseases like depression, cardiovascular disease, and epilepsy [25].

1.1 Genome Sequencing in Everyday Medicine

WGS and WES have become more widely used in hospitals as the price of genetic testing has been lowered. These methods help doctors to find the specific genetic origin of rare diseases that can be missed by regular tests [26] [27]. In a very short time, genome sequencing is able to find the reason for a condition that is causing a person's life to be in danger, thus giving doctors the opportunity to choose exact and personalized treatments. Currently, comprehensive genomic profiling (CGP) is a cancer care tool used to help clinicians locate the druggable mutations, i.e., the precise genetic abnormalities that can be fixed with medications [28]. Studies report that patients who receive treatment tailored to the genetics of their tumours live longer and have better therapy outcomes [29]. Genomic information is being more and more integrated with electronic health records (EHRs) with the aim of helping doctors to choose the right therapies [30]. Nevertheless, challenges remain, such as sorting out uncertain genetic results, training doctors, and making sure that testing is available and affordable to everyone.

1.2 Gene-Editing and New Genetic Therapies

Any genetic target within living cells may be precisely manipulated using the CRISPR-based gene editing technology to produce the required sequence modifications [31]. Furthermore, base editing and prime editing produce even more delicate and accurate modifications without creating double-strand breaks [32]. With the potential to significantly improve human health, advances in genome editing technology have produced a wide range of applications, from fundamental scientific discoveries to the creation of new medications [33] [34].

However, before gene therapy is safe and accessible for clinical usage, a number of important issues still need to be resolved. Finding more effective ways to deliver drugs that target certain cells, reduce immunological responses, and eliminate other adverse consequences is critical [35]. These treatments are also hard to come by, especially in places with little resources, because of their high cost and ethical issues. This highlights the importance of finding more accessible and scalable alternatives [33]. To ensure proper use, ethical concerns–particularly those related to gene editing that might be passed down to future generations–need to be carefully regulated and further studied.

1.3. Pharmacogenomics: Matching Drugs to DNA

Pharmacogenomics is a technique that uses a person's genetic composition to determine the best medication and dosage for them [36]. Genes like CYP2C19, CYP2D6, and HLA-B can affect how a person responds to a medication combination for a particular problem, such as epilepsy, depression, or heart disease [37] [38]. The example is the use of genetic testing by doctors to discover the antidepressants that will most probably work for a patient and in which the side effects are minimal [39]. As a result of the increased use of clinical decision-support technologies, pharmacogenomics is being deployed in new therapy areas such as neurology and psychiatry [40].

In brief, precision medicine has become a clinical reality that is based on pharmacogenomic profiling, CRISPR-based editing, and genomic sequencing to provide targeted medicines. As these technologies evolve and get more affordable, they hold the promise of a highly personalized care. Nevertheless, issues such as complicated data, ethical problems, and poor access are still around. To ensure its fair and successful implementation, strict regulations, clinical standards, and funding for a long time are needed.

2. Artificial Intelligence in Clinical Practice

AI has become one of the key factors in the areas of diagnostics, predictive analytics, and clinical decision support. With the advancement of machine learning (ML) and deep learning (DL) techniques, AI systems are able to detect diseases more accurately by analysis of imaging data, electronic health records (EHRs), and other large clinical datasets. Several studies [41], [42] have shown that machine learning algorithms have outperformed human experts in detecting diabetic retinopathy, breast cancer, and COVID-19 pneumonia from radiological images. The application of AI in radiology has become the most impactful and visible in areas like mammography screening, lung nodule identification, and chest X-ray classification. The main benefit of such tools is to enable urgent abnormalities to be prioritized thus a reduction of the physician's workload and time to diagnosis can be achieved [43]. In a recent article, the importance of AI in the revolution of

radiology was depicted but it was also pointed out that human supervision is still necessary. AI-driven instruments are being progressively adopted in electronic health records (EHRs) for the purposes of risk stratification, automated triaging, and clinical workflow management [44]. Besides imaging, AI is also reaching into EHR systems and other clinical platforms to offer assistance in risk stratification, outcome prediction, and workflow optimization. According to one systematic survey of health-system leaders in the United States, there is a gradual implementation of AI-based prediction models and decision-support tools which is in line with the increasing acknowledgment of AI's potential [45].

Another important area of research is natural language processing, or NLP. Real-time monitoring of patient outcomes and adverse drug responses is made possible by the use of natural language processing (NLP) to extract structured data from unstructured clinical notes [46]. Integration of unstructured clinical data, such as discharge summaries, pathology reports, and doctor's notes, into decision-making systems has been a challenge. NLP is applied to these free-text sources to extract relevant information, such as patient outcomes, drug interactions, and adverse drug events (ADEs) [47]. Besides, NLP and ML methods can detect ADEs in the free-text part of EHR with higher sensitivity than that of the raised in the text [8].

Moreover, pharmacovigilance is being improved through the use of transformer-based models that extract and interpret ADR (adverse drug response) signals from biological literature and social media material [48].

Compared to traditional regression-based methods, AI-based models for risk prediction and screening have shown better discrimination [49]. Over the last thirty years, the volume of research and the clinical interest have been increasing as a result of which recent studies on AI in healthcare, which is its influence in such areas as genomics, workflow tools, and diagnostics, have been cited [50] [51].

Even with these trailblazing advancements, the implementation of AI safely, fairly, and successfully in clinical practice brings along substantial restrictions and difficulties that must be overcome. The first issue is the quality of training data for AI, as well as their representativeness and completeness, which are still matter of debate; in fact, incomplete or biased datasets can worsen health inequities and increase the number of errors by AI systems [52]. The second issue concerns AI models' interpretability and openness, which are still problems. Clinicians and regulators usually expect that AI systems can provide a clear "reasoning", especially if high-stake decisions are involved [53]. For example, the integration of multimodal data–imaging, EHR, and genomics–not only opens new possibilities but also complicates the design and validation phases.

Thirdly, the authors pinpoint regulatory, ethical, and legal issues as the most significant ones. These comprise among others worries about data privacy, consent, algorithmic bias, and accountability for errors, and the need for prospective validation in different clinical settings [54]. Fourthly, on one hand, operational and technical issues such as expense, clinical workflow integration, compatibility with current EHR system, and user training might slow down the transition of research to standard care. On the other hand, "last-mile" deployment in real-world scenarios is still a problem [55].

In brief, AI is slowly but surely being merged with clinical workflows in order to provide decision support, monitoring, prediction, and diagnosis. With further improvements in algorithms, computing infrastructure, and integration into health systems, AI has the potential to increase the care accuracy, speed, and consistency. However, to fully benefit from AI, it will be necessary to solve issues related to data quality, equity, and transparency, to clinical workflow integration of AI tools, and to governance. The progression of AI will be the lead to the partnership of smart systems and human clinicians, which will thus generate a future where clinical decisions are more timely, personalized, and better-informed.

Applications	Clinical Area	Example Tools or Outcomes	References
Imaging Diagnostics	Ophthalmology, Radiology	Diabetic retinopathy detection	[41]
EHR Risk Stratification	Internal Medicine	Predictive analytics for sepsis	[44]
Natural Language Processing	All Clinical Domains	Adverse event detection	[46]
Genomics and Precision Medicine	Oncology, Rare Diseases	Drug response prediction and variant interpretation by AI for personalized therapy	[46]
Clinical Decision Support	Intensive Care, Emergency Medicine	Predicting patient deterioration and optimizing ICU triage decisions	[56]
Mental Health and Neurology	Psychiatry, Cognitive Disorders	Analysis of speech and facial cues for early diagnosis of depression and Alzheimer's disease	[57]
Drug Discovery and Pharmacology	Pharmacogenomics, Drug Development	Identification and predicting drug efficacy and toxicity	[58]

3. Liquid Biopsy and Non-Invasive Diagnostics

Early illness identification and monitoring are being revolutionized by the development of liquid biopsy techniques, which use blood, saliva, or urine to detect biomarkers. Exosomal RNA and circulating tumour DNA (ctDNA) are promising for therapeutic resistance prediction, minimal residual illness detection, and early cancer screening [59], [60].

For the non-invasive diagnosis of systemic illnesses like diabetes, mouth cancer, and neurodegenerative diseases, saliva-based diagnostics are also becoming more popular [61].

Recent large reviews and clinical studies emphasize that ctDNA can detect relapse earlier than imaging in many cancers and guide timely therapeutic changes, though sensitivity is still limited for very low tumour burden [62]. Exosomal RNA (including microRNAs and other non-coding RNAs packaged inside extracellular vesicles) offers complementary advantages: exosomes are stable in body fluids, reflect tumour and tumour-microenvironment biology, and can carry RNA signatures that enable early detection, prognostication, and insights into mechanisms of progression and immune escape [63]. Multiple 2024-2025 reviews report robust progress in exosomal-ncRNA biomarker discovery and multi-omic profiling strategies that combine exosomal RNA with ctDNA and protein markers to improve accuracy [64].

Technological advances raising clinical utility include tumour-informed assays (which track patient-specific mutations), ultra-deep sequencing, fragmentomics (ctDNA fragment size/pattern analysis), methylation profiling, and machine-learning models that integrate signals across modalities [65]. In trial settings, these approaches have significantly heightened sensitivity and decreased false positives. However, the differences in analytics between platforms and the compromise between sensitivity and specificity still remain as major obstacles to the use of screening on a large scale. The next substantial improvements in this area are most probably to come from: (1) multi-analyte tests combining ctDNA, exosomal RNA/proteins, and other biomarkers to achieve the highest possible sensitivity and specificity; (2) the uniformity of pre-analytic and analytic pipelines implemented by the different laboratories; and (3) prospective patient outcome studies (rather than just earlier detection) to demonstrate the benefits. In that case, liquid biopsy has the potential to revolutionize early detection, make adjuvant therapy more patient-specific by using MRD status, and provide the opportunity for intervention at an earlier stage of therapeutic resistance – all with the least possible invasiveness for patients [65].

4. The Human Microbiome in Clinical Health

Our knowledge of host-microbe interactions in health and illness has grown as a result of microbiome research. Autoimmune illnesses, obesity, irritable bowel syndrome, and even neurodevelopmental abnormalities are now associated with dysbiosis [66]. Fecal microbiota transplantation (FMT) is being investigated for inflammatory bowel disease and autism spectrum disorder, and it has shown great efficacy in treating recurrent Clostridium difficile infections [67] [68]. The microbiome, a last layer of the immune system and a source of infection treatment, can be altered by probiotics, prebiotics, and synbiotics [69].

The gut, skin, and mucosa are home to trillions of bacteria, viruses, fungi, and archaea that make up the microbiome, which is an essential system for immunity, metabolism, and neurobehavioral regulation [70], [71]. An imbalance in the microbiome known as dysbiosis is linked to the emergence of autoimmune diseases like type 1 diabetes, metabolic disorders like obesity, and gastrointestinal conditions like IBD [72], [73]. Patients with inflammatory bowel disease (IBD) often exhibit a decrease in microbial diversity and an increase in pathogenic taxa, resulting in more severe chronic inflammation [72]. Besides that, changes in the microbiota are also correlated with various neuropsychiatric and neurodevelopmental disorders such as depression and autism spectrum disorder (ASD) [74].

The most important components of human gut microbiota, Firmicutes and Bacteroidetes, are the bacteria that produce short-chain fatty acids (SCFAs), which are the main factors for immunological regulation, the source of energy for colonocytes, and the epithelial barrier integrity [75]. The fact that destroying these microbial networks may result in the weakening of systemic immunity and gut barrier function very much shows the importance of the therapeutic methods that have been employed.

One of the most revolutionary therapeutic means of microbiome research is faecal microbiota transplantation (FMT).
Cure rates for recurrent Clostridium difficile infections have gone beyond 80–90% according to the results of randomized trials [76]. In addition to eliminating pathogens, FMT modifies immunity, increases SCFA synthesis, and restores microbial diversity, all of which lower inflammation and improve host metabolic and immunological processes [75] [77]. In addition to C. difficile, preliminary research has shown benefits in symptoms and behaviour in ulcerative colitis, Crohn's disease, metabolic syndrome, and ASD [78].

Probiotics, prebiotics, and synbiotics are further methods of microbiome manipulation. While prebiotics like inulin specifically promote beneficial taxa [80], probiotics like Lactobacillus fortify epithelial barriers and inhibit pathogens [79]. Synbiotics are being investigated for their synergistic benefits in critical care, cancer, and liver disease [81]. Probiotics of the next generation, such as Faecalibacterium prausnitzii and Akkermansia muciniphila, have potent anti-inflammatory and barrier-protective properties [82].

Systemic medicines are also influenced by the microbiome; for example, gut diversity predicts improved outcomes with immune checkpoint inhibitors in cancer [83]. Future developments could create precision microbial consortia by combining synthetic biology, CRISPR editing, and bacteriophage therapy [84] [85].
5. Neuroimmunology and Brain Health
One of the biggest changes in medicine has been the combination of neurology and immunology to create new drugs. To name a few, monoclonal antibodies against amyloid beta like Lecanemab in Alzheimer's disease and B-cell depleting agents in multiple sclerosis have been the major breakthroughs[85][86]. Furthermore, brain organoids made from stem cells serve as models for neurodevelopmental and neurodegenerative disorders, thus, they are a great tool for personalized drug testing and disease modelling [87].

After the merge of immunology and neurology, the therapy of neurodegenerative and demyelinating diseases has been radically changed. Alzheimer's disease (AD) is a case which still puzzles scientists. It is a progressive brain disorder which is the main cause of death in the elderly and affects more than 6.5 million Americans. It is characterized by the accumulation of amyloid beta plaques, tau tangles, synaptic loss, and neuronal degeneration. As a matter of fact, it is not completely understood how the disease progresses but nevertheless, the last years have witnessed ground-breaking developments in monoclonal antibody therapies targeting amyloid pathology[88][89][90].

Monoclonal Antibodies in Alzheimer's disease
Alzheimer's disease, a neurodegenerative disorder that impairs brain functions progressively and is characterized by amyloid-β plaques, tau tangles, and loss of neurons, has been a tough nut to crack in terms of disease-modifying therapies. For a long time, the treatment approaches were only symptomatic, thus having very little effect on disease progression. On the other hand, the arrival of monoclonal antibodies has made a big change in the expectations.

It has been demonstrated by the agents such as lecanemab and donanemab, that the cognitive decline can be slowed down if amyloid pathology is targeted. Lecanemab in the phase 3 Clarity AD trial removed amyloid plaques and brought about a slowing of cognitive decline that was quite small but still of some significance. The changes in Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores were less (1.21 vs 1.66; difference −0.45, 95% CI −0.67 to −0.23) [88]. Donanemab in the same way, halted the progression of the disease in its early stage; in the TRAILBLAZER-ALZ 2 trial, patients with low/medium tau had a difference of −0.67 in 76-week CDR-SB as compared to placebo [89]. The outcomes of these studies were the basis for the drug regulatory agencies giving the green light for the use in therapy: FDA gave the nod to lecanemab in 2023 and donanemab (Kisunla) in the middle of 2024 [90].

However, both treatments are linked to infusion responses and amyloid-related imaging abnormalities (ARIA), necessitating careful patient selection and continuous monitoring. Longer-term research is still necessary to evaluate long-term safety and effect durability. However, the approval of anti-amyloid antibodies provides evidence that disease modification is feasible and demonstrates how immunotherapy has transformed therapeutic options in AD.

B-cell Depleting Therapies in Multiple Sclerosis
One example of how immune processes can be targeted to improve chronic neurological disease is multiple sclerosis (MS). Anti-CD20 monoclonal antibodies decrease neuroinflammation by specifically depleting CD20+ B cells and a subset of CD20+ T cells.

Agents such as ocrelizumab, of atumumab, and most recently ublituximab have consistently demonstrated reduced relapse rates, slower disability progression, and favourable outcomes compared with older standards of care. In the OPERA I/II trials, ocrelizumab lowered the annualized relapse rate by ~46-47% (0.16 vs 0.29) and halved the risk of 12-week confirmed disability progression versus interferon-β. Ofatumumab achieved similar efficacy in the ASCLEPIOS I/II trials, reducing relapse rates (ARR 0.11 vs 0.22) and decreasing 3-month confirmed disability progression (HR≈0.66) relative to teriflunomide. Most recently, ublituximab, tested in the ULTIMATE I/II trials, demonstrated superior relapse reduction compared with teriflunomide, with FDA approval granted in late 2022 and integration into guidelines during 2023-24 [91].

Their efficacy has been so compelling that international guidelines now recognize anti-CD20 therapies as first-line, high-efficacy options for relapsing MS, with ocrelizumab also expanding therapeutic possibilities for primary progressive disease. Beyond their direct clinical benefits, these therapies illustrate how insights into B-cell biology have reframed MS pathogenesis.

Brain Organoids in Neurological Research
Though immunotherapies are changing the face of treatment, progress in stem cell-derived brain organoids is fundamentally altering the study of neurological diseases. The researchers can look at changes in neuronal development and degeneration in a patient-specific context through these 3D models that mirror human brain anatomy.

The integration of the immune cells in organoid systems has opened the way for many understanding of neuroinflammation. For example, microglia-containing organoids made from patients with ALS, Parkinson's disease, and dementia have demonstrated increased inflammatory signalling and poor amyloid clearance. In a similar fashion, research using organoid models with CRISPR-based high-throughput screening to uncover the genetic regulators of neuronal development has been greatly sped up, thus directly linking mutations to functional cellular phenotypes [92] [93].

These breakthroughs point to the use of personalized, mechanistic platforms as a way of supporting immunotherapy: on the one hand, the latter shows how immune modulation can change disease course; on the other hand, organoids offer the experimental framework for the identification and refinement of novel drugs. The integration of immunology and organoid-based modelling is a step towards precision, mechanism-based strategies in brain health whereby therapeutic development and personalized modelling can mutually reinforce and thus expedite the translation process to yield sustained clinical benefits.

6. mRNA and Next-Generation Vaccine Technologies

Novel mRNA platforms are being studied for influenza, Zika virus, RSV, and possibly cancer, building on the success of mRNA vaccines against COVID-19 [94]. A customized immunological approach to cancer treatment is provided by personalized neoantigen vaccines, which are adapted to a patient's tumour-specific mutations [95].

Lipid nanoparticles and self-amplifying RNA are examples of delivery system advancements that promise higher vaccine efficacy with lower dosages [96].

Table 2: Comparison of mRNA Vaccine Applications

Target Disease	Vaccine Type	Status as of 2025
COVID-19	mRNA-based	Approved globally [94]
Cancer (personalized)	Neoantigen mRNA	Ongoing trials [95]
RSV & Zika Virus	mRNA-based	Pre-approval phase [94]

mRNA vaccine technology has revolutionized modern medicine, offering rapid, scalable, and highly effective protection against infectious diseases, while next-generation vaccine platforms and delivery methods are set to further advance global immunization efforts [94].

Core Principles of mRNA Vaccines

mRNA or messenger RNA vaccine technology involves the introduction of man-made mRNA into the body. This leads the cells to create a particular protein, usually a viral antigen, which in turn, results in the activation of the adaptive immune response [94]. The process does not interfere with the recipient's DNA. It is also non-infectious and safe since mRNA is naturally degraded in the cell [97]. Besides these, the mRNA-based vaccines are quick to be designed as the scientists can easily develop a new vaccine by simply changing the mRNA code. Additionally, mRNA vaccines can be used in several fields other than COVID-19, for example, the vaccines for the flu, Zika, rabies, cytomegalovirus, and even cancer immunotherapy have been made possible by mRNA technology [98].

Recent Advancements in mRNA Technology

The fast and continuous molecular reengineering of mRNA has paved the way for the stabilizing, immunizing, and even large-scale production of vaccines to be improved. Among the innovations are [94]:

- LNPs or lipid nanoparticle (LNP) carriers that both shield the mRNA and make the delivery of the latter inside the cell easier [97].
- Changing nucleosides and mRNA sequences to increase protein production and decrease immune system activation at the natural level [99].
- Self-replicating mRNA (saRNA) which increases the antigen fed by a lower dose.

The outbreak of COVID-19 has been a proof for mRNA to be the technology behind quick and wide vaccine rolling-out cellular [97]. Pfizer-BioNTech and Moderna vaccines were two such examples of high efficacy [97].

mRNA (messenger RNA) vaccine technology works by delivering synthetic mRNA into the body, prompting cells to produce a specific protein, often a viral antigen, which then activates an adaptive immune response [94]. This process does not alter the recipient's DNA and is considered non-infectious and safe, as the mRNA breaks down naturally within the cell [97]. Key benefits include speed of design, as scientists can rapidly create new vaccines by tweaking the mRNA code, and versatility, as mRNA vaccines have shown potential beyond COVID-19, including for influenza, Zika, rabies, cytomegalovirus, and even cancer immunotherapy [98].

Recent Advancements in mRNA Technology

Rapid progress in the molecular engineering of mRNA has led to improvements in vaccine stability, immunogenicity, and manufacturing scale. Innovations include [94]:

- Lipid nanoparticle (LNP) carriers that protect mRNA and facilitate cellular uptake [97].
- Modified nucleosides and mRNA sequences to increase protein translation and minimize innate immune activation [99].
- Self-amplifying mRNA (saRNA), which boosts antigen expression using lower doses.
  The COVID-19 pandemic highlighted mRNA's ability to enable quick, large-scale vaccine deployment, with Pfizer-BioNTech and Moderna vaccines showing high efficacy [97].

Next-Generation Vaccine Technologies

Emerging platforms extend well beyond classic mRNA approaches:

- Self-amplifying RNA and circular RNA both offer enhanced stability and immunogenicity for longer-lasting immune responses and dose sparing.
- Microneedle patches and oral formulations enable needle-free and potentially self-administered vaccines, improving access and compliance, especially in resource-poor regions.
- Nanoparticle-based carriers and ionizable lipids further improve delivery and efficacy, while cell-based vaccine platforms are being developed for influenza and other pathogens.
- AI-driven antigen design and immunoinformatics are now integral to rapidly personalizing and optimizing vaccine targets.

Applications and Future Outlook

With continuous efforts being made for influenza, RSV, and new viruses, the prevention of infectious diseases continues to be the main focus of mRNA and next-generation vaccines. Using mRNA's flexibility to encode specific tumor antigens, personalized cancer vaccines and immunotherapies are exciting new developments [100]. Molecular biology, digital health, and material science will probably work together in the future to increase vaccination accessibility and expedite pandemic response [97].

7. Targeted and Immuno-Oncology Therapies

Oncology is changing as a result of tumour-agnostic therapies that target genetic abnormalities rather than the source of the tumour. Treatments such as pembrolizumab (for MSI-high tumours) and larotrectinib (for NTRK fusion-positive cancers) have demonstrated effectiveness in a variety of cancer types [101].

Tumour-agnostic (also known as tissue-agnostic) therapies represent a significant change in oncology: instead of treating tumours based on the organ of origin, doctors increasingly focus on the molecular or genetic factors that are common to various tumour types [102]. The first significant example was pembrolizumab (Keytruda), which established the tissue-agnostic regulatory pathway and was approved by the FDA in May 2017 for any solid tumour with a particular biomarker (microsatellite instability-high / mismatch-repair deficient, MSI-H/dMMR) [103]. That approval showed durable responses across disparate histologies and opened the door for molecularly guided, tumour-independent treatment decisions. Shortly after, targeted small molecules followed: larotrectinib (VITRAKVI) and entrectinib (ROZLYTREK) were approved to treat NTRK-fusion positive solid tumours regardless of site – a powerful proof-of-concept that rare but highly actionable fusions can be treated effectively across cancer types [104]. Larotrectinib demonstrated high overall response rates and durable remissions in both adults and children, leading to its initial accelerated approval (2018) and, more recently, regulatory milestones toward full approval. Entrectinib received approval in 2019 for the same biomarker-defined population [105].

Since those early approvals the tumour-agnostic portfolio has expanded to include other biomarker classes and modalities. Antibody-drug conjugates (for example, fam-trastuzumab deruxtecan-nxki / T-DxD) and additional checkpoint inhibitor indications (tumour-mutational-burden high (TMB-H), other mismatch-repair indications), as well as newer targeted agents for RET, BRAF, and other alterations, have been developed or granted tissue-agnostic labels in some jurisdictions or on the basis of pan-tumour trial designs [106]. These approvals illustrate two practical lessons: (1) actionability depends on both the target biology and the context (tumour histology can modulate efficacy), and (2) broad genomic testing (NGS panels, companion diagnostics) is now essential to identify patients who could benefit [107]. Chimeric antigen receptor T-cell (CAR-T) therapy has extended from hematologic malignancies to solid tumours, with next-generation constructs focusing on improved specificity and reduced toxicity [108].

8. Cardiovascular Innovations

Recent advancements in cardiovascular medicine include gene therapy for familial cardiomyopathies, minimally invasive procedures like transcatheter aortic valve replacement (TAVR), and novel anticoagulants with enhanced safety profiles [109], [110]. Gradually, wearable technology such as smartwatches is being linked with cardiovascular monitoring systems in order to make the diagnosis of atrial fibrillation and also the monitoring of blood pressure continuous and easy.

Major developments in cardiovascular medicine have turned the field into one of precision-based treatments and less invasive interventions. For instance, familial cardiomyopathies are going to be redefined as "genetically druggable" in the context of gene therapy [112]. A review, for instance, discussing this issue, illustrates the advent of gene therapy cardiac technologies as a treatment for monogenic myocardial disorders and those genetically based such as arrhythmogenic right ventricular cardiomyopathy and sarcomeric-gene hypertrophic cardiomyopathy [113]. The technologies mentioned involve the use of gene replacement, gene silencing, and gene-editing vectors.

The possibility of developing treatments that address the underlying molecular etiology of dilated cardiomyopathy (DCM) and other inherited variations rather than merely treating symptoms is growing as the genetics of these conditions become more understood [114].

In structural and interventional cardiology, the development of less invasive techniques such as Transcatheter Aortic Valve Replacement (TAVR) has significantly changed patient care. With sustained five-year results, a decreased mortality/stroke composite, and improved valve hemodynamic, recent trials in low-risk patients demonstrate that TAVR can produce comparable (and in some endpoints superior) results to surgical aortic-valve replacement [115]. The trend toward less invasive, more broadly applicable procedures is further highlighted by the development of novel platforms and the widening of indications (e.g., for aortic regurgitation rather than stenosis).

Lastly, new anticoagulant approaches are still being developed. In addition to being more convenient than warfarin and heparin, the so-called novel oral anticoagulants (NOACs) and direct oral anticoagulants (DOACs) have superior safety profiles in a number of populations. Recent systematic reviews and meta-analyses demonstrate favourable efficacy and safety even in "special" populations (e.g., morbidly obese individuals with atrial fibrillation) [115].

NOACs may be associated with greater rates of short-term adverse events, according to a single-center research done following TAVR, although these findings are still theoretical and underscore the need for more comprehensive prospective trials and tailored anticoagulant selection [116].

9. Epigenetic Therapies

Essential focal substances in cancer and neuropsychiatric diseases are epigenetic alterations, which are changes in gene expression that can be inherited but do not involve changes to the DNA sequence. Clinical trials for depression and blood malignancies are testing medications that target DNA methylation and histone deacetylase (HDAC) [117]. Tools like CRISPRoff enable reversible gene silencing without altering the underlying DNA [118].

In cancer biology, aberrant epigenetic regulation is ubiquitous: promoter hypermethylation of tumour-suppressor genes, global DNA hypomethylation leading to genomic instability, dysregulated histone deacetylation resulting in gene silencing, and altered chromatin architecture all contribute to malignant transformation and progression [119].

Therapeutic agents–so-called “epi-drugs”–have thus been developed. Among these, inhibitors of DNA methyltransferases (DNMTi, such as 5-azacitidine and decitabine) and histone deacetylase inhibitors (HDACi) are the most mature clinically: they restore expression of epigenetically silenced genes, reactivate apoptotic pathways, induce cell-cycle arrest and sensitize tumours to other therapies [120].

For example, recent reviews note that combinations of DNMTi or HDACi with immune-checkpoint inhibitors or other treatments are showing promise across malignancies. One analysis observed that 45 drugs synergised with DNMTi/HDACi to reactivate tumour-suppressor gene expression, while 85 were antagonistic–underscoring the importance of careful combination-therapies [121].

Additionally, a 2025 review in Molecular Cancer outlined how HDAC inhibitors like vorinostat and romidepsin (approved in T-cell lymphoma) are now being explored in solid tumours (lung, breast, hepatocellular) and combined with immunotherapy in ongoing trials [122] [123].

In the neuropsychiatric/ neurological sphere, epigenetic dysregulation is also emerging as an important mechanism. Altered DNA methylation patterns and histone modification changes have been implicated in disorders such as schizophrenia, major depressive disorder, Alzheimer’s disease and other neurodegenerative illnesses [124].

Clinical studies are underway: for instance, a phase 3 trial of the HDAC inhibitor Entinostat combined with exemestane in hormone-receptor positive advanced breast cancer had acceptable safety and extension of progression-free survival, while an early trial of entinostat/vor-inostat in Alzheimer’s disease is exploring maximal tolerable dose [124].

Nevertheless, several major challenges remain. First, patient selection and biomarkers are still nascent: epigenetic heterogeneity is vast and context-specific (cell-type, tumour-type, region in brain). Second, off-target effects and toxicities (given the broad role of epigenetic modifiers in normal tissues) are non-trivial. Third, the timing and combinatorial strategy of epi-drugs (with chemotherapy, immunotherapy, targeted therapy or psychotropics) require optimization. As one review stated: “understanding the epigenetic regulation of immune cells in the tumour micro-environment provides the rationale for improving immunotherapy outcomes” but also emphasises the complexity of that network [121].

Table 3: Select Gene and Cell Therapy Milestones (2024-2025)

Technology/Method	Clinical Use	Current Status
CRISPR-Cas9	Sickle cell disease, Beta thalassemia	Phase II/III trials [24]
CAR-T therapy (next-gen)	Solid tumors	Early clinical trials [108]
Induced Pluripotent Stem Cells	Retinal & Parkinson’s disease	Translational research [125]

10. Regenerative and Stem Cell Therapies

Cell-based therapies are advancing in many medical fields like orthopaedics, neurology, and cardiology. Mesenchymal stem cells (MSCs) are under investigation for autoimmune diseases like rheumatoid arthritis. Mesenchymal stem cells (MSCs) have gained significant attention due to their regenerative and immunomodulatory properties. Clinical studies have demonstrated that MSC transplantation can reduce inflammation, promote tissue repair, and improve functional outcomes in conditions such as rheumatoid arthritis and osteoarthritis [125] [126]. MSCs act mainly through paracrine signalling, releasing growth factors and cytokines that suppress pro-inflammatory pathways and enhance tissue healing. According to recent research, MSC therapy may also promote brain regeneration and heart tissue repair following ischemia injury [127].

Another significant advancement in regenerative medicine is induced pluripotent stem cells (iPSCs), which were initially created from adult fibroblasts by Takahashi and associates [128], [125]. Because these cells may differentiate into almost any kind of tissue, damaged cells can be replaced in a patient-specific manner without the ethical conundrums that come with using embryonic stem cells. With promising pre-clinical and early clinical results, iPSCs are being investigated for retinal regeneration in macular degeneration and as dopaminergic neuron replacements in Parkinson's disease models [130].

Furthermore, functional tissues and organ scaffolds for transplantation are being created using 3D bioprinting [131]. In parallel, 3D bioprinting technologies are emerging as a complementary platform to engineer tissue scaffolds and organ constructs for transplantation. Using bioinks composed of living cells, growth factors, and biomaterials, researchers can fabricate structures that mimic the architecture and mechanical properties of native tissues [131]. Recent progress in vascularized tissue printing has expanded potential applications in bone, cartilage, and cardiac tissue engineering [132].

Despite these promising advances, major challenges remain, including the need to optimize cell sourcing, delivery, long-term safety, and regulatory approval. However, the combination of MSCs, iPSCs, and 3D bioprinting has revolutionary potential for functional tissue replacement and customised regenerative medicine.

11. Digital Health and Telemedicine

Telehealth also known as Telemedicine is a strategy for providing health care services remotely. It has emerged since the Covid-19 pandemic into a mainstream model of care [133]. Over the past five years healthcare systems have increasingly integrated emote patient monitoring, tele-consultations, remote patient monitoring and digital therapies into routine practice [134] [135]. Without compromising patient satisfaction or follow-up rates, these innovations have revolutionized patient-provider interactions, improved care continuity, and saved a substantial amount of time [136].

The ability of telemedicine to close access gaps to care is one of its most revolutionary effects. Geographical and financial obstacles frequently cause patients in underserved, rural, or resource-constrained settings to miss out on timely care [137]. Scalable solutions provided by digital health platforms enable earlier interventions and lessen the burden of travel. Although disparities in digital literacy, broadband access, and affordability continue to be major obstacles, systematic reviews verify that these tools are especially helpful for marginalized populations [138] [139]. To guarantee the equitable implementation of telehealth services, these issues must be resolved.
Numerous randomized controlled trials have confirmed the clinical efficacy of telemedicine. This is most likely the reason for starting new businesses, establishing commercial enterprises, and offering virtual care services. For patients with advanced non-small cell lung cancer, telehealth-delivered early palliative care produced quality-of-life outcomes comparable to in-person visits, according to a large multicenter trial [140]. Similarly, the effectiveness of telemedicine follow-up care for overactive bladder was comparable to that of in-person visits [141]. Treatment through telemedicine was considered by both patients and providers to be more convenient and engaging for patients, while also maintaining clinical effectiveness, in the management of chronic diseases [142]. These results demonstrate telemedicine's ability to provide safe, effective, and patient-centered treatment in a variety of clinical settings.

Additionally, an increasing number of research have focused on how digital health affects the interaction between patients and providers. According to research, using virtual platforms can improve communication, promote shared decision-making, and give patients a bigger say in how their chronic illnesses are managed [143]. However, other doctors worry that a decrease in in-person interactions could lead to a depersonalization of care and a loss of confidence. Efficiency and relational continuity may be maximized by hybrid care models that integrate digital technology with conventional interactions [144].

Strong infrastructure, interoperable electronic health records, and well-established assessment methods are necessary for telemedicine system-level integration. The necessity of uniform outcome measurements to guide the safe application of laws and regulations is highlighted by a systematic evaluation of RCTs. Cost-effectiveness, patient outcomes, and patient-centeredness are a few examples of these indicators [145]. Future advancements in digital health, like more comprehensive wearable sensor integration, AI-assisted triage, and customized digital medications, are anticipated to have the potential to lower healthcare costs and enhance predictive therapy [146]. Furthermore, virtual healthcare assistants and chatbots powered by AI are improving patient engagement and adherence [147].

In essence, both telemedicine and digital health have evolved from just being tentative tools to validated, evidence-based approaches that are, in fact, reshaping the manner in which healthcare is delivered nowadays. Even though issues related to fairness and incorporation into the system are still present, the extensive evidence from research is backing up the promise of such technologies to make patient outcomes better, accessibility higher, and resource use more efficient. The digital health will keep on changing the patient care to be more like the future of the past, rather than of the present, if this progress can be maintained through sustained innovation, rigorous evaluation, and the use of equitable implementation strategies.

12. Psychedelic-Assisted Therapy

One of the most fascinating areas of psychiatry is psychedelic-assisted treatment (PAT). It combines planned psychotherapy sessions with tightly monitored use of drugs like psilocybin, MDMA, or ketamine. Patients with otherwise treatment-resistant diseases may have quick and occasionally long-lasting benefits with PAT, which typically only requires a few guided sessions as opposed to traditional daily drugs. The medical profession is starting to investigate how these treatments might be safely and successfully incorporated into practice, and research has intensified during the last ten years [148].

Clinical evidence and regulatory landscape

Psilocybin has been singled out for special attention among the different agents. One or two guided sessions with psilocybin, along with preparatory and integration therapy, have been shown in clinical trials to have a powerful effect in lowering the symptoms of major depressive disorder and treatment-resistant depression [149]. As a result of these results, the U.S. Food and Drug Administration (FDA) has assigned the 'Breakthrough Therapy' status to psilocybin-based treatments, thus indicating their potential [150]. But, the storage of long-term data is still a challenge, and many of the trials have a relatively small number of participants.

Research on MDMA-assisted therapy has been primarily focused on PTSD (post-traumatic stress disorder). The large phase-3 trials showed a significant alleviation of the PTSD symptoms in the treatment groups as compared to the placebo, thus resulting in an upbeat outlook that MDMA might get approval for medical use shortly [151]. Nonetheless, the FDA in 2024, rejected the application, seeking additional data and more rigorous safety reporting [152]. The decision points to the difference between the strict standards that must be met for clinical approval and the positive results of the trials.

Ketamine as well as its enantiomer esketamine are quite a different pair of compounds. Rather, they have been in use medically. For instance, intranasal esketamine is approved to be used for treatment-resistant depression and for depressive symptoms in patients with suicidal thoughts [153]. Ketamine is one which makes symptoms disappear quickly but is often short-lived, therefore repeated dosing is the norm. Hence, the availability of ketamine can serve as a model of how psychedelic therapies might be delivered within existing health systems, but it at the same time brings up the issues of cost, monitoring, and the possibility of misuse.

As the underlying neurobiology is still an ongoing research, psychedelics seem to work on brain networks which regulate mood, cognition, and perception. For instance, psilocybin dramatically activates serotonin 2A receptors, thus for a short period of time it "loosens" interaction of brain circuits and neural plasticity is promoted [154]. Several patients report that the sessions were very significant in a sense that the trauma and depressive thought cycles were reinterpreted. Since almost all contemporary methods involve meticulous preparation, guidance during dosage, and integration sessions afterward, the therapeutic setting is essential [155]. This psychological framework not only reduces possible risks but also makes it possible for the drug experience to have a lasting therapeutic effect.

Safety, ethics, and challenges

Using psychedelics in therapy is not without risks. Patients can experience fear, anxiety, and even have side effects involving their cardiovascular system, such as high blood pressure, while on medication. "Bad trips" may be emotionally destabilizing if the patient is not properly guided. Besides the fear of drug interactions if treatments are extended too fast, there is also concern about the possibility of drug abuse [156]. To minimize the risks, standardized methods, safety registries from the real world, and training programs for therapists using psychedelics are being developed.

Access is yet another ethical dilemma. There is a question of whether in the future access will only be limited to rich people or those living in big cities because the first studies have been done in specialist academic centers. The policy, the insurance coverage, and the development of the staff will have to be very carefully planned in order to achieve the necessary equilibrium. Experts say that commercialization should not go beyond the safety infrastructure or the proof [157].

The road ahead

Larger, independent studies with longer follow-up are needed for the next phase of study to ascertain the durability of benefits. Comparisons with traditional therapies like cognitive-behavioural therapy or medications will further highlight PAT's role in the therapeutic toolbox. Cost-effectiveness assessments will be essential when health systems determine whether to support novel methods [158].

At the same time, innovation continues to flourish. New psilocybin analogues, deuterated drugs, and combination therapies are under development. Thanks to both governmental and private financing, psychedelic research is expanding rapidly. In the future years, it will be established whether PAT becomes a transformative psychiatric intervention or remains confined to specialist settings.

Depression that is resistant to treatment, PTSD, and anxiety disorders can be relieved with the use of psilocybin, MDMA, and ketamine, as evidenced by clinical trials. Consequently, regulatory agencies are gradually permitting the use of these substances in psychotherapy sessions with certain limitations [146][147].

Psychedelic-assisted therapy is a radical change in the way mental health issues are addressed. Initial studies suggest that it could offer rapid relief to patients who have not responded to traditional treatments. However, it is necessary to have the zeal along with the care. We are reminded that definite, clear data is needed before any large-scale implementation, hence, regulatory obstacles, safety issues, and ethical problems are still there. PAT may prove to be a useful addition to conventional treatments if further research validates the current findings, serving as a reminder that sometimes healing entails both neurobiology and a carefully regulated human experience [159].

Address for Correspondence Dr Mehnaz Khan, Junior Resident, Department of Pathology, Era's Lucknow Medical College & Hospital, Era University, Lucknow, Uttar Pradesh, India- 226003 Email- mehnazkhan0102@gmail.com
DOI: 10.5455/im.98589

references

1. Hassan, Mubashir et al. "Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review." International journal of molecular sciences vol. 23,9 4645. 22 Apr. 2022.
2. Molla, Getnet, and Molalegne Bitew. "Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives." Biomedicines vol. 12,12 2750. 30 Nov. 2024.
3. Jamalinia, Mohamad, and Ralf Weiskirchen. "Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment." Annals of translational medicine vol. 13,2 (2025): 18.
4. Davis, Daniel J, and Sai Goutham Reddy Yeddula. "CRISPR Advancements for Human Health." Missouri medicine vol. 121,2 (2024): 170-176.
5. Qahwaji, Rowaid et al. "Pharmacogenomics: A Genetic Approach to Drug Development and Therapy." Pharmaceuticals (Basel, Switzerland) vol. 17,7 940. 13 Jul. 2024
6. Hernandez, Marta et al. "Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments." Pharmaceutics vol. 16,2 244. 7 Feb. 2024
7. Bajwa, Junaid et al. "Artificial intelligence in healthcare: transforming the practice of medicine." Future healthcare journal vol. 8,2 (2021): e188-e194.
8. Golder, Su et al. "Leveraging Natural Language Processing and Machine Learning Methods for Adverse Drug Event Detection in Electronic Health/Medical Records: A Scoping Review." Drug safety vol. 48,4 (2025): 321-337.

9. Rojas-Carabali, William et al. “Natural Language Processing in medicine and ophthalmology: A review for the 21st-century clinician.” Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) vol. 13,4 (2024): 100084.
10. Maleki Varnosfaderani, Shiva, and Mohamad Forouzanfar. “The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century.” Bioengineering (Basel, Switzerland) vol. 11,4 337. 29 Mar. 2024
11. Weiner, Ellison B et al. “Ethical challenges and evolving strategies in the integration of artificial intelligence into clinical practice.” PLOS digital health vol. 4,4 e0000810. 8 Apr. 2025.
12. Connal, Siobhan et al. “Liquid biopsies: the future of cancer early detection.” Journal of translational medicine vol. 21,1 118. 11 Feb. 2023.
13. Ma, Liwei et al. “Liquid biopsy in cancer current: status, challenges and future prospects.” Signal transduction and targeted therapy vol. 9,1 336. 2 Dec. 2024.
14. Liu, Zhiting et al. “Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis.” Biomarker research vol. 12,1 153. 5 Dec. 2024.
15. Hou, Kaijian et al. “Microbiota in health and diseases.” Signal transduction and targeted therapy vol. 7,1 135. 23 Apr. 2022.
16. Durack, Juliana, and Susan V Lynch. “The gut microbiome: Relationships with disease and opportunities for therapy.” The Journal of experimental medicine vol. 216,1 (2019): 20-40.
17. Bulut, Sena Davran et al. “Recent Insights About Probiotics Related Pharmabiotics in Pharmacology: Prevention and Management of Diseases.” Probiotics and antimicrobial proteins vol. 17,4 (2025): 2262-2292.
18. Della Rocca, Ylenia et al. “Stem Cells in Regenerative Medicine: A Journey from Adult Stem Cells to Induced Pluripotent Cells.” International journal of molecular sciences vol. 26,17 8255. 26 Aug. 2025.
19. Skarlis, Charalampos et al. “Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions.” International journal of molecular sciences vol. 26,19 9398. 26 Sep. 2025.
20. Kruk-Słomka, Marta et al. “New Approaches to the Treatment of Alzheimer's Disease.” Pharmaceuticals (Basel, Switzerland) vol. 18,8 1117. 26 Jul. 2025.
21. Haleem, Abid et al. “Telemedicine for healthcare: Capabilities, features, barriers, and applications.” Sensors international vol. 2 (2021): 100117.
22. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
23. Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313(21):2119-2120.
24. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
25. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-350.
26. Stark Z, et al. Integrating genomic sequencing into healthcare: policy and evidence challenges. Nat Rev Genet. 2024;25(2):88-104.
27. Wright CF, et al. Making new genetic diagnoses with WGS in rare diseases. Nat Med. 2024;30(1):15-23.
28. Chae YK, et al. Clinical impact of precision oncology trials. JCO Precis Oncol. 2024;8(1):e2300120.
29. Denny JC, Collins FS. Precision medicine in 2030: the journey ahead. Cell. 2024;187(3):491-507.
30. Zhang Y, et al. Integration of genomics into EHRs for clinical decision support. JMIR Biomed Inform. 2024;5:e55632.
31. Komor AC, et al. Programmable editing of a target base in genomic DNA. Nature. 2016;533(7603):420-424.
32. Anzalone AV, et al. Search-and-replace genome editing without double-strand breaks. Nature. 2019;576(7785):149-157.
33. Baylis F, et al. Ethical governance of human genome editing. Science. 2023;382(6673):1032-1037.
34. Lanphier E, et al. Don’t edit the human germ line. Nature. 2015;519(7544):410-411.
35. Hacein-Bey-Abina S, et al. Immunological challenges in gene therapy. Nat Immunol. 2024;25(5):712-722.
36. Qahwaji, Rowaid et al. “Pharmacogenomics: A Genetic Approach to Drug Development and Therapy.” Pharmaceuticals (Basel, Switzerland) vol. 17,7 940. 13 Jul. 2024.
37. Karnes, Jason H et al. “Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.” Clinical pharmacology and therapeutics vol. 109,2 (2021): 302-309.
38. Omran, Safa et al. “Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions.” European journal of human genetics : EJHG, 10.1038/s41431-025-01950-6. 24 Sep. 2025.
39. Wang, Xinrui et al. “Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT.” BMC psychiatry vol. 23,1 334. 12 May. 2023.
40. Ajibade, Victoria M, and Chidinma S Madu. “The Integration of Artificial Intelligence Into Precision Medicine for Neuro-Oncology: Ethical, Clinical, and Nursing Implications in Immunotherapy Care.” Cureus vol. 17,5 e85024. 29 May. 2025.
41. Gulshan V, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy. JAMA. 2016;316(22):2402-2410.
42. Esteva A, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115-118.
43. Mello-Thoms, Claudia, and Carlos A B Mello. “Clinical applications of artificial intelligence in radiology.” The British journal of radiology vol. 96,1150 (2023): 20221031.
44. Rajkomar A, et al. Scalable and accurate deep learning with electronic health records. NPJ Digit Med. 2018;1:18.
45. Poon, Eric G et al. “Adoption of artificial intelligence in healthcare: survey of health system priorities, successes, and challenges.” Journal of the American Medical Informatics Association : JAMIA vol. 32,7 (2025): 1093-1100.
46. Savova GK, et al. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J Am Med Inform Assoc. 2010;17(5):507-513.
47. Kreimeyer, Kory et al. “Natural language processing systems for capturing and standardizing unstructured clinical information: A systematic review.” Journal of biomedical informatics vol. 73 (2017): 14-29.
48. Hussain, Sajid et al. “Pharmacovigilance with Transformers: A Framework to Detect Adverse Drug Reactions Using BERT Fine-Tuned with FARM.” Computational and mathematical methods in medicine vol. 2021 5589829. 13 Aug. 2021.
49. Kong, Sung Hye. “Incorporating Artificial Intelligence into Fracture Risk Assessment: Using Clinical Imaging to Predict the Unpredictable.” Endocrinology and metabolism (Seoul, Korea) vol. 40,4 (2025): 499-507.
50. Alowais, Shuroug A et al. “Revolutionizing healthcare: the role of artificial intelligence in clinical practice.” BMC medical education vol. 23,1 689. 22 Sep. 2023.
51. Xie, Yaojue et al. “Evolution of artificial intelligence in healthcare: a 30-year bibliometric study.” Frontiers in medicine vol. 11 1505692. 15 Jan. 2025.
52. Kelly, Christopher J et al. “Key challenges for delivering clinical impact with artificial intelligence.” BMC medicine vol. 17,1 195. 29 Oct. 2019.
53. Abbas, Qaiser et al. “Explainable AI in Clinical Decision Support Systems: A Meta-Analysis of Methods, Applications, and Usability Challenges.” Healthcare (Basel, Switzerland) vol. 13,17 2154. 29 Aug. 2025.
54. Naik, Nithesh et al. “Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility?.” Frontiers in surgery vol. 9 862322. 14 Mar. 2022.
55. Nair, Monika et al. “A comprehensive overview of barriers and strategies for AI implementation in healthcare: Mixed-method design.” PloS one vol. 19,8 e0305949. 9 Aug. 2024.
56. Komorowski, Matthieu et al. “The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care.” Nature medicine vol. 24,11 (2018): 1716-1720.
57. Cummins, Nicholas et al. “Speech analysis for health: Current state-of-the-art and the increasing impact of deep learning.” Methods (San Diego, Calif.) vol. 151 (2018): 41-54.
58. Zhavoronkov, Alex et al. “Deep learning enables rapid identification of potent DDR1 kinase inhibitors.” Nature biotechnology vol. 37,9 (2019): 1038-1040.
59. Wan JCM, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238.

60. Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858-873.
61. Yoshizawa JM, et al. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev. 2013;26(4):781-791.
62. Boukouris, A.E., Michaelidou, K., Joosse, S.A. et al. A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer. npj Precis. Onc. 9, 178 (2025). https://doi.org/10.1038/s41698-025-00984-9.
63. Zhu M, Gao Y, Zhu K, Yuan Y, Bai H, Meng L. Exosomal miRNA as biomarker in cancer diagnosis and prognosis: A review. Medicine (Baltimore). 2024 Oct 18;103(42):e40082. doi: 10.1097/MD.0000000000040082.
64. Ghosh, S., Rajendran, R.L., Mahajan, A.A. et al. Harnessing exosomes as cancer biomarkers in clinical oncology. Cancer Cell Int 24, 278 (2024). https://doi.org/10.1186/s12935-024-03464-5.
65. Ma, L., Guo, H., Zhao, Y. et al. Liquid biopsy in cancer: current status, challenges and future prospects. Sig Transduct Target Ther 9, 336 (2024). https://doi.org/10.1038/s41392-024-02021-w.
66. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-141.
67. van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.
68. Kang DW, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):10.
69. Hill C, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514.
70. Lazar V, et al. Human microbiome: from intrinsic microbial resilience to inducible microbiome therapies. Nat Rev Microbiol. 2023;21(4):250-71.
71. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-41.
72. Khan I, et al. Role of gut microbiota in human health and disease. Front Cell Infect Microbiol. 2024;14:1357921.
73. Khan M, Ahmad S, Pratap PD. Microbial dysbiosis and associated human diseases. GSC Adv Res Rev. 2024;20(2):21-35.
74. Cryan JF, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877-913.
75. Khan M, et al. Rebalancing the gut ecosystem: Fecal microbiota transplantation. Int J Med Public Health. 2025;15(1):89-97.
76. van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-15.
77. Rai S, Anwar S, Khan M. Fecal microbiota transplantation: A comprehensive review. Era J Med Res. 2024;11(1):71-75.
78. Kang DW, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms. Microbiome. 2017;5(1):10.
79. Hill C, et al. Expert consensus document: The ISAPP consensus statement on probiotics. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-14.
80. Slavin J. Fiber and prebiotics: Mechanisms and health benefits. Nutrients. 2013;5(4):1417-35.
81. Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021.
82. Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol. 2017;8:1765.
83. Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy in epithelial tumors. Science. 2018;359(6371):91-7.
84. Zmora N, et al. Personalized gut mucosal colonization resistance to probiotics. Cell. 2018;174(6):1388-405.
85. Mimee M, et al. Microbiome therapeutics: Advances and challenges. Cell Syst. 2018;6(1):5-15.
86. Hauser SL, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234.
87. Lancaster MA, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501(7467):373-379.
88. Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21.
89. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease. JAMA. 2023;330(1):33-44.
90. Ramanan VK, Day GS. Anti-amyloid monoclonal antibody therapies for Alzheimer disease: from clinical trials to practice. Mol Neurodegener. 2023;18(1):45.
91. Steinman L, Fox EJ, Arnold DL, Hartung H-P, Havrdova EK, Selmaj K, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704-16.
92. Meng X, Liu L, Li M, Li D, Yang Y, Chen Y, et al. High-throughput CRISPR screening in human brain organoids identifies regulators of neuronal development. Nature. 2023;618(7965):583-90.
93. Li C, He Y, Xu W, Wang J, Chen X, Zhang X, et al. Patient-derived brain organoids reveal cell-type-specific pathogenesis of autism spectrum disorders. Nature. 2023;619(7970):475-82.
94. Pardi, N., Hogan, M., Porter, F. et al. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov 17, 261-279 (2018). https://doi.org/10.1038/nrd.2017.243.
95. Sahin U, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222-226.
96. Schlake T, et al. mRNA as novel technology for passive immunotherapy. Cell Mol Life Sci. 2019;76(2):301-328.
97. Al Fayez N, Nassar MS, Alshehri AA, Alnefaie MK, Almughem FA, Alshehri BY, Alawad AO, Tawfik EA. Recent Advancement in mRNA Vaccine Development and Applications. Pharmaceutics. 2023 Jul 18;15(7):1972. doi: 10.3390/pharmaceutics15071972.
98. Overmars I, Au-Yeung G, Nolan TM, Steer AC. mRNA vaccines: a transformative technology with applications beyond COVID-19. Med J Aust. 2022 Jul 18;217(2):71-75. doi: 10.5694/mja2.51620.
99. Wei Z, Zhang S, Wang X, Xue Y, Dang S and Zhai J (2025) Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects. Front. Immunol. 16:1524317. doi: 10.3389/fimmu.2025.1524317.
100. Overmars I, Au-Yeung G, Nolan TM, Steer AC. mRNA vaccines: a transformative technology with applications beyond COVID-19. Med J Aust. 2022 Jul 18;217(2):71-75. doi: 10.5694/mja2.51620. Epub 2022 Jul 3.
101. Drilon A, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739.], [Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
102. Vranic, S., Basu, G. D., Hall, D. W., & Gatalica, Z. (2022). Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group. Acta Medica Academica, 51(1), 217-231. https://doi.org/10.5644/ama2006-124.392
103. Lemery, S., Fashoyin-Aje, L., Marcus, L., Casak, S. J., Schneider, J. A., Theoret, M. R., Kluetz, P. G., Pazdur, R., & Beaver, J. A. (2022). Development of Tissue-Agnostic Treatments for Patients with Cancer. Annual Review of Cancer Biology, 6(1), 147-165. https://doi.org/10.1146/annurev-cancerbio-060921-021828
104. Iannantuono, G. M., Torino, F., Rosenfeld, R., Guerriero, S., Carlucci, M., Sganga, S., Capotondi, B., Riondino, S., & Roselli, M. (2022). The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 23(15), 8535. https://doi.org/10.3390/ijms23158535
105. Roncati, L., & Palmieri, B. (2019). Tissue-agnostic cancer drugs in the fight against molecular subsets of metastases of unknown origin. 6, 378-379. https://doi.org/10.18632/ONCOSCIENCE.492
106. Thein KZ, Myat YM, Park BS, Panigrahi K, Kummar S. Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development. Cancers. 2024; 16(14):2529. https://doi.org/10.3390/cancers16142529
107. Mun J, Lim B. The hallmarks of tissue-agnostic therapies and strategies for early anticancer drug discovery. Drug Discov Today. 2024;29(12):104203. doi:10.1016/j.drudis.2024.104203
108. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73.
109. Zsebedics M, et al. Gene therapy for cardiovascular diseases: state-of-the-art. Genes. 2022;13(5):762.
110. Mack MJ, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.
111. Perez MV, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909-1917.

112. Venturiello D, Tiberi PG, Perulli F et al. “Unveiling the Future of Cardiac Care: A Review of Gene Therapy in Cardiomyopathies.” Int. J. Mol. Sci. 2024;25(23):13147.
113. Mundisugih J, Ravindran D, Kizana E. “Exploring the Therapeutic Potential of Gene Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy.” Biomedicines. 2024;12(6):1351.
114. Eldemire R, Mestroni L, Taylor MRG. Genetics of Dilated Cardiomyopathy. Annu Rev Med. 2024;75:417-426. doi:10.1146/annurev-med-052422-020535
115. Elfar, S., Mahmoud, S.A., Hamdi, S. et al. The safety and efficacy of nonvitamin K antagonist oral anticoagulants in morbidly obese patients with atrial fibrillation: a meta-analysis. BMC Cardiovasc Disord 24, 74 (2024). https://doi.org/10.1186/s12872-024-03731-3
116. Rodriguez Mejia, R.A.; Acker, E.; Dao, V.; Rana, H. Novel Oral Anticoagulants Versus Antiplatelet Therapy in Post-TAVR Patients: A Single-Center Retrospective Study. J. Clin. Med. 2025, 14, 4690. https://doi.org/10.3390/jcm14134690
117. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27.
118. Nuñez JK, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184(9):2503-2519.
119. Patnaik, E.; Madu, C.; Lu, Y. Epigenetic Modulators as Therapeutic Agents in Cancer. Int. J. Mol. Sci. 2023, 24, 14964. https://doi.org/10.3390/ijms241914964.
120. Suraweera A, O'Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44(1):37. Published 2025 Feb 26. doi:10.1007/s10555-025-10253-7
121. Ji, Y., Xiao, C., Fan, T. et al. The epigenetic hallmarks of immune cells in cancer. Mol Cancer 24, 66 (2025). https://doi.org/10.1186/s12943-025-02255-4
122. Vickram S, Infant SS, Sivasubramanian M, Anbalagan S, Marimuthu MMC, Chopra H. Epigenetic modulation in cancer drug discovery: promising targets and clinical applications. Pharmacol Rep. Published online September 2, 2025. doi:10.1007/s43440-025-00770-1.
123. Tahghighi, A., Seyedhashemi, E., Mohammadi, J. et al. Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies. Clin Epigenet 17, 34 (2025). https://doi.org/10.1186/s13148-025-01844-w.
124. Li, Jennie Z.; Ramalingam, Nagendran; Li, Shaomin*. Targeting epigenetic mechanisms in amyloid-β-mediated Alzheimer’s pathophysiology: unveiling therapeutic potential. Neural Regeneration Research 20(1):p 54-66, January 2025. | DOI: 10.4103/NRR.NRR-D-23-01827.
125. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts. Cell. 2007;131(5):861-872.
126. Pirsadeghi, Ali et al. “Therapeutic approaches of cell therapy based on stem cells and terminally differentiated cells: Potential and effectiveness.” Cells & development vol. 177 (2024): 203904.
127. Shammaa R, El-Kadiry AE, Abusarah J, Rafei M. Mesenchymal stem cells beyond regenerative medicine. Front Cell Dev Biol. 2020;8:72.
128. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829-848.
129. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts. Cell. 2007;131(5):861-872.
130. Doi D, Magotani H, Kikuchi T, et al. Human induced pluripotent stem cells in Parkinson’s disease: first-in-human clinical trial. NPJ Parkinsons Dis. 2020;6(1):28.
131. Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014;32(8):773-785.
132. Zhang YS, Yue K, Aleman J, et al. 3D bioprinting for tissue and organ fabrication. Ann Biomed Eng. 2017;45(1):148-163.
133. Telehealth is here to stay. Nat. Med. 2021, 27, 1121.
134. Greer JA, Tramontano AC, Safonov A, Guo Y, Cole S, Chiu J, et al. Telehealth vs in-person early palliative care for patients with advanced non-small cell lung cancer: A randomized clinical trial. JAMA. 2025;333(7):573-83.
135. Li X, Wang P, Sun J, Hu L, Huang T. Enabling telemedicine from the system-level perspective: Scoping review. J Med Internet Res. 2025;27:e65932.
136. Mossback S, Inoyatov I, Fonseca P, Du C, Lee E, Ruan H, et al. A randomized controlled trial comparing telemedicine versus in-person office visits for the follow-up of overactive bladder. Urogynecology (Philia). 2022;28(12):819-24.
137. Gajarawala SN, Pelkowski JN. Telehealth benefits and barriers. J Nurse Pract. 2020 Oct 21;17(2):218-21. doi: 10.1016/j.nurpra.2020.09.013.
138. Maita KC, Maniaci MJ, Haider CR, Avila FR, Torres-Guzman RA, Borna S, Lunde JJ, Coffey JD, Demaerschalk BM, Forte AJ. The impact of digital health solutions on bridging the healthcare gap in rural areas: A scoping review. Perm J. 2024 Aug 13;28(3):130-43. doi: 10.7812/TPP/23.134.
139. Petretto DR, Masala I, Zuddas C. Telemedicine, e-health, and digital health equity: A scoping review. Clin Pract Epidemiol Ment Health. 2024;20:e17450179279732.
140. Sten-Gahmberg S, Pedersen K, Harsheim IG, Hansen AH, Løseth A. Experiences with telemedicine-based follow-up of chronic conditions: The views of patients and health personnel enrolled in a pragmatic randomized controlled trial. BMC Health Serv Res. 2024;24:10732.
141. Senek M, Taylor B, Farrow C, Griffiths P. The impact of digital health solutions on the patient-provider relationship in respiratory disease: Systematic review. J Med Internet Res. 2025;27:e70970.
142. Wilson S, Tolley C, Mc Ardle R, Beswick E, Slight SP. Key Considerations When Developing and Implementing Digital Technology for Early Detection of Dementia-Causing Diseases Among Health Care Professionals: Qualitative Study. J Med Internet Res. 2023 Aug 22;25:e46711. doi: 10.2196/46711.
143. Sugawara Y, Nakamura Y, Lee SH, Li M, Cho S. Metrics for evaluating telemedicine in randomized controlled trials, 2019-2024: Systematic review. J Med Internet Res. 2025;27:e67929.
144. Topol EJ. High performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019; 25(1):44-56.
145. Bickmore TW, et al. Patinet and consumer safety risks when using conversationall assistants for medical information. JAMA Intern Med. 2018;178(2):269-270.
146. Carhart-Harris RL, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627.
147. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033.
148. Breeksema JJ, et al. Patient perspectives and experiences with psilocybin treatment. Front Psychiatry. 2024.
149. Yao Y, et al. Efficacy and safety of psychedelics in mental health: A meta-analysis. J Affect Disord. 2024.
150. U.S. FDA. Psilocybin receives Breakthrough Therapy designation. 2023.
151. Mithoefer MC, et al. MDMA-assisted therapy for PTSD: Phase 3 trial results. Nat Med. 2023.
152. U.S. FDA statement on MDMA therapy approval decision. 2024.
153. FDA. Esketamine (Spravato) prescribing information. 2024.
154. Carhart-Harris RL, et al. Neural mechanisms of psychedelic therapy. Cell Rep. 2022.
155. Johnson MW, et al. Human hallucinogen research: Guidelines for safety. J Psychopharmacol. 2019.
156. Reiff CM, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020.
157. Nutt D, et al. The ethics of psychedelic medicine. Lancet Psychiatry. 2021.
158. Romeo R, et al. Cost-effectiveness of psilocybin therapy. Health Econ Rev. 2023.
159. Carhart-Harris RL & Goodwin GM. The future of psychedelic psychiatry. World Psychiatry. 2024.